Chronic hepatitis C virus (HCV) disease burden and cost in the United States

Abstract

Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding of HCV disease progression and the associated cost can help the medical community manage HCV and develop treatment strategies in light of the emergence of several potent anti-HCV therapies. A system dynamic model with 36 cohorts was used to provide maximum flexibility and improved forecasting. New infections incidence of 16,020 (95% confidence interval, 13,510-19,510) was estimated in 2010. HCV viremic prevalence peaked in 1994 at 3.3 (2.8-4.0) million, but it is expected to decline by two-thirds by 2030. The prevalence of more advanced liver disease, however, is expected to increase, as well as the total cost associated with chronic HCV infection. Today, the total cost is estimated at $6.5 ($4.3-$8.4) billion and it will peak in 2024 at $9.1 ($6.4-$13.3) billion. The lifetime cost of an individual infected with HCV in 2011 was estimated at $64,490. However, this cost is significantly higher among individuals with a longer life expectancy. Conclusion: This analysis demonstrates that US HCV prevalence is in decline due to a lower incidence of infections. However, the prevalence of advanced liver disease will continue to increase as well as the corresponding healthcare costs. Lifetime healthcare costs for an HCV-infected person are significantly higher than for noninfected persons. In addition, it is possible to substantially reduce HCV infection through active management.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 47

1. 1.

   Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.

   Not in our library10.7326/0003-4819-144-10-200605160-00004

2. 2.

   Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-278.

   Not in our library10.7326/0003-4819-156-4-201202210-00004

3. 3.

   Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107-115.

   Not in our library10.1111/j.1365-2893.2006.00785.x

4. 4.

   El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.

   Not in our library10.1056/nejm199903113401001

5. 5.

   Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095-2100.

   Not in our library10.1016/s0140-6736(03)15109-4

6. 6.

   Organ Procurement and Transplantation Network (OPTN). 2011.

   Not in our library

7. 7.

   Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care. 2005;21:55-65.

   Not in our library10.1017/s0266462305050075

8. 8.

   Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-865.

   Not in our library10.7326/0003-4819-127-10-199711150-00001

9. 9.

   Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol. 2001;36:870-876.

   Not in our library10.1080/003655201750313414

10. 10.

    Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis. 2006;38:497-505.

    Not in our library10.1080/00365540500532803

11. 11.

    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569.

    Not in our library10.2105/ajph.90.10.1562

12. 12.

    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228-237.

    Not in our library10.1001/jama.290.2.228

13. 13.

    Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866-874.

    Not in our library10.7326/0003-4819-127-10-199711150-00002

14. 14.

    Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg. 2007;70:177-187.

    Not in our library

15. 15.

    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-521.

    Not in our library10.1053/j.gastro.2009.09.067

16. 16.

    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int. 2011;31(Suppl 2):4-17.

    Not in our library10.1111/j.1478-3231.2011.02535.x

17. 17.

    McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531-546.

    Not in our library10.18553/jmcp.2011.17.7.531

18. 18.

    El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012;19:153-160.

    Not in our library10.1111/j.1365-2893.2011.01563.x

19. 19.

    Human mortality database. 2012.

    Not in our library

20. 20.

    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY. 1999;30:1318-1324.

    Not in our library10.1002/hep.510300518

21. 21.

    Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY. 2009;50:1750-1755.

    Not in our library10.1002/hep.23220

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ. 2007;56:1-24.

    Not in our library

24. 24.

    Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ. 2008;57:1-24.

    Not in our library

25. 25.

    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ. 2009;58:1-27.

    Not in our library

26. 26.

    Consumer Price Index Bureau of Labor Statistics USDoL. 2010.

    Not in our library

27. 27.

    Viral hepatitis surveillance, United States 2010 National Center for HIV SaTPDoHASB. 2010.

    Not in our library

28. 28.

    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383-398.

    Not in our library10.1016/j.cld.2005.05.003

29. 29.

    Disease Burden from Viral Hepatitis A, B, and C in the United States Centers for Disease Control and Prevention. 2010.

    Not in our library

30. 30.

    National Health and Nutrition Examination Survey Data, 2009-2010 Centers for Disease Control and Prevention. National Center for Health Statistics. 2012.

    Not in our library

31. 31.

    Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.

    Not in our library10.1046/j.1537-2995.2002.00174.x

32. 32.

    Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50:1495-1504.

    Not in our library10.1111/j.1537-2995.2010.02622.x

33. 33.

    Armstrong GL. Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med. 2007;167:166-173.

    Not in our library10.1001/archinte.167.2.166

34. 34.

    Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. HEPATOLOGY. 2007;46:37-47.

    Not in our library10.1002/hep.21662

35. 35.

    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.

    Not in our library10.1056/nejmoa0808010

36. 36.

    Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999;44:874-880.

    Not in our library10.1136/gut.44.6.874

37. 37.

    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832.

    Not in our library10.1016/s0140-6736(96)07642-8

38. 38.

    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY. 2002;36(5 Suppl 1):S47-S56.

    Not in our library10.1053/jhep.2002.36993

39. 39.

    Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. HEPATOLOGY. 1999;29:1215-1219.

    Not in our library10.1002/hep.510290401

40. 40.

    Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int. 2011;31(Suppl 1):18-22.

    Not in our library10.1111/j.1478-3231.2010.02378.x

Cited by papers we hold 3

• Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study · 2019
  Not checked
• Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 · 2018
  No notice
• Global distribution and prevalence of hepatitis C virus genotypes · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.